<p>Researchers at The Hong Kong Polytechnic University (PolyU) have developed an imaging biomarker, the Tumour Heterogeneity Index (THI), which enables noninvasive assessment of breast cancer patients' response to AKT inhibitors before treatment, helping clinicians identify patients most likely to bene</p>